All‐cause mortality ( · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
It is very uncertain whether intramuscular injection of bone marrow mononuclear cells (BMMNC) changes all‐cause mortality ( compared with control (very low certainty).
1 finding from 1 review
Reduction in pain Various scales including VAS, PISQ; scales ranged from 0 to 4/10/100, where 0 = no pain ( · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
1 finding from 1 review
Amputation · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
It is very uncertain whether intramuscular injection of bone marrow mononuclear cells (BMMNC) changes incidence of amputation ( compared with control (very low certainty).
1 finding from 1 review
Angiographic analysis · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Increase in ABI An ABI ratio of 0.9 or less indicates PAD. Values between 0.9 and 1.0 are borderline, and above 1.0 is considered normal ( · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
1 finding from 1 review
Increase in PFWD (m) ( · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
1 finding from 1 review
Complications and side effects · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard therapy
It is very uncertain whether intramuscular injection of bone marrow mononuclear cells (BMMNC) changes side effects and complications ( compared with control (very low certainty).
1 finding from 1 review
Adverse events: preterm delivery · women undergoing assisted reproduction
Intrauterine infusion/injection of autologous platelet‐rich plasma may leads to higher adverse events: preterm delivery compared with no intervention or placebo (low certainty).
1 finding from 1 review
Live birth or ongoing pregnancy · women undergoing assisted reproduction
It is very uncertain whether intrauterine infusion/injection of autologous platelet‐rich plasma changes live birth (or ongoing pregnancy) compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Miscarriage · women undergoing assisted reproduction
It is very uncertain whether intrauterine infusion/injection of autologous platelet‐rich plasma changes miscarriage compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Clinical pregnancy · women undergoing assisted reproduction
It is very uncertain whether intrauterine infusion/injection of autologous platelet‐rich plasma changes clinical pregnancy compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Adverse event ‐ multiple pregnancy · women undergoing assisted reproduction
It is very uncertain whether intrauterine infusion/injection of autologous platelet‐rich plasma changes adverse events: multiple pregnancy compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Adverse events: ectopic pregnancy · women undergoing assisted reproduction
It is very uncertain whether intrauterine infusion/injection of autologous platelet‐rich plasma changes adverse events: ectopic pregnancy compared with no intervention or placebo (very low certainty).
1 finding from 1 review
Postoperative pain or distress · Children and young people aged 17 years or younger having dental treatment (including extractions) under general anaesthesia (secondary…
1 finding from 1 review
Because of substantial clinical and methodological heterogeneity in the studies, we were unable to determine an estimate of effect
1 study · 54 participants
Very low
Participant satisfaction · Children and young people aged 17 years or younger having dental treatment (including extractions) under general anaesthesia (secondary…
The review found no eligible studies for this question.
1 finding from 1 review
Intraoperative or postoperative bleeding · Children and young people aged 17 years or younger having dental treatment (including extractions) under general anaesthesia (secondary…
The review found no eligible studies for this question.
1 finding from 1 review
Physiological parameters (cardiac/respiratory events; type and volume of GA drug) · Children and young people aged 17 years or younger having dental treatment (including extractions) under general anaesthesia (secondary…
The review found no eligible studies for this question.
1 finding from 1 review
Parental satisfaction · Children and young people aged 17 years or younger having dental treatment (including extractions) under general anaesthesia (secondary…
The review found no eligible studies for this question.
1 finding from 1 review
Lip or cheek biting, numbness or allergy · Children and young people aged 17 years or younger having dental treatment (including extractions) under general anaesthesia (secondary…
The review found no eligible studies for this question.
1 finding from 1 review
Postoperative anxiety · Children and young people aged 17 years or younger having dental treatment (including extractions) under general anaesthesia (secondary…
1 finding from 1 review